An LC-MS/MS method development for dapagliflozin-loaded nanostructured lipid carrier formulation in rabbit plasma

Year 2024, Volume: 28 Issue: 2 , 438 - 446 , 28.06.2025

Burcu Üner

https://izlik.org/JA38BD33DK

Abstract

The primary goal of this study was to develop and validate an LC-MS/MS method for the detection of dapagliflozin in nanostructured lipid carriers (NLC) using ion-interaction chromatography. The reversed-phase InfinityLab Poroshell 120 (150 × 4.6 mm, 4 µm) column, using a mobile phase of acetonitrile-25 mM ammonium acetate solution with pH 4.1 (35:65, v/v), effectively separated the analytes and their internal standards. This method has been thoroughly tested and validated to ensure accurate and reliable results. To improve sensitivity and selectivity, mass spectrometry was used in polarity switching mode. In order to study ion transitions for dapagliflozin in both positive and negative mode, multiple reaction monitoring mode was utilized, with the ion transitions being m/z 467.1 [M+CH3COO]- /329.1. The assay's linear calibration range for dapagliflozin was established from 0.05-150 ng/mL to improve drug pharmacokinetics assessment. The analyte's limit of detection (LOD) and limit of quantitation (LOQ) were 0.07 and 0.35 ng/mL, respectively. After testing, no interference was observed in plasma matrices from different sources, including haemolysed and lipemic plasma. The impact of Dapagliflozin-loaded NLC on plasma levels were investigated using this method.

Keywords

Nanostructured lipid carriers , quantitative method , SGLT-2 inhibitors , dapagliflozin , plasma extraction

References

• [1] Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79: 1135-1146. https://doi.org/10.1007/s40265-019-01148-3
• [2] Khan T, Khan S, Akhtar M, Ali J, Najmi AK. Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice. Neurochem Int. 2021; 150: 115-131. https://doi.org/10.1016/j.neuint.2021.105158
• [3] Uner BY, Yesildag O. SGLT-2i: Nanoparticular-Based strategies, solutions, and clinical applications in opposition to low bioavailability. J Pharm Innov. 2023; 1-7. https://doi.org/10.1007/s12247-023-09789-4
• [4] Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015; 19(4): 524–528. https://doi.org/10.4103/2230-8210.157859
• [5] Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and cardiovascular outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380: 347-357. https://doi.org/10.1056/nejmoa1812389
• [6] Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Honorio JWC, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387: 1089-1098. https://doi.org/10.1056/NEJMoa2206286
• [7] Chitra KP, Eswaraiah MC, Basaveswararao M. Effect of various superdisintegrants on immediate release formulations of SGLT2 inhibitor dapagliflozin. Int J Res Appl Nat Social Sci. 2017; 23: 1-5.
• [8] He X, Li Y, Ma YS, Fu Y, Xun X, Cui Y, Dong Z. Development of UPLC-MS/MS method to study the pharmacokinetic ınteraction between sorafenib and dapagliflozin in rats. Molecules. 2022; 27(19): 6190. https://doi.org/10.3390/molecules27196190
• [9] Ji QC, Xu X, Ma E, Liu J, Basdeo S, Liu G, Mylott W, Boulton DW, Shen JX, Stouffer B, Aubry AF, Arnold ME. Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies. Anal Chem. 2015; 87(6): 3247–3254. https://doi.org/10.1021/ac5037523
• [10] de Bruin TWA, Reele S, Hamer-Maansson JE, Parikh S, Tang W. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clin Pharmacol Drug Dev. 2016; 5: 118-130. https://doi.org/10.1002/cpdd.220
• [11] Lee HW, Kang WY, Park JS, Lee JH, Gwon MR, Yang DH, Kim EH, Park SJ, Yoon YR, Seong SJ. Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects. Transl Clin Pharmacol. 2023; 31: 105-113. https://doi.org/10.12793/tcp.2023.31.e10
• [12] Muller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN & NLC): Present state of development & industrial applications. Curr Drug Discov Technol. 2011; 8: 207-227. https://doi.org/10.2174/157016311796799062
• [13] Uner B, Ozdemir S, Yıldırım E, Yaba A, Tas C, Uner M, Ozsoy Y. Loteprednol loaded nanoformulations for corneal delivery: Ex-vivo permeation study, ocular safety assessment and stability studies. J Drug Deliv Sci Technol. 2023; 81: 104252. https://doi.org/10.1016/j.jddst.2023.104252
• [14] Shaveta S, Singh J, Afzal M, Kaur R, Imam SS, Alruwaili NK, Alharbi KS, Alotaibi NH, Alshammari MS, Kazmi I, Yasir M, Goyel A, Ameeduzzafar. Development of solid lipid nanoparticle as carrier of pioglitazone for amplification of oral efficacy: formulation design optimization, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol. 2020; 57: 101674. https://doi.org/10.1016/j.jddst.2020.101674
• [15] Uner B, Macit MSM. Anti-obesity effects of chlorogenic acid and caffeine-loaded lipid nanoparticles through PPAR-γ/ C/EBP-a pathways. Int J Obes. 2023; 47(11): 1108-1119. https://doi.org/10.1038/s41366-023-01365-7
• [16] Mohsin K, Alamari R, Ahmad A, Raish M, Alanzi F, Hussain MD. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug. Int J Nanomed. 2016: 2829-2838. https://doi.org/10.2147/IJN.S104187
• [17] Aubry AF, Gu H, Magnier R, Morgan L, Xu X, Tirmenstein M, Wang B, Deng Y, Cai J, Couerbe P, Arnold M. Validated LC–MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis. 2010; 2: 2001-2009. https://doi.org/10.4155/bio.10.139
• [18] El-Zaher AA, Hashem HA, Elkady EF, Allam MA. A validated LC-MS/MS bioanalytical method for the simultaneous determination of dapagliflozin or saxagliptin with metformin in human plasma. Microchem J. 2019; 149: 104017. https://doi.org/10.1016/j.microc.2019.104017
• [19] Surendran S, Paul D, Pokharkar S, Deshpande A, Giri S, Satheeshkumar N. A LC-MS/MS method for simultaneous estimation of a novel anti-diabetic combination of saxagliptin and dapagliflozin using a polarity switch approach: application to in vivo rat pharmacokinetic study. Anal Methods. 2019; 11: 219-226. https://doi.org/10.1039/C8AY02087F
• [20] Shah JV, Shah PA, Shah PV, Sanyal M, Shrivastav PS. Fast and sensitive LC-MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma. J Pharm Anal. 2017; 7: 163-169. https://doi.org/10.1016/j.jpha.2016.11.004
• [21] Khomitskaya Y, Tikhonova N, Gudkov K, Erofeeva S, Holmes V, Dayton B, Davies N, Boulton DW, Tang W. Bioequivalence of dapagliflozin/metformin extended-release fixed-combination drug product and single-component dapagliflozin and metformin extended-release tablets in healthy Russian subjects. Clin Ther. 2018; 4: 550-561. https://doi.org/10.1016/j.clinthera.2018.02.006
• [22] Van der Aart-van der Beek AB, Wessels AMA, Heerspink HJL, Touw DJ. Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. J Chromatogr B. 2020; 1152: 122257. https://doi.org/10.1016/j.jchromb.2020.122257